IGF-1 LR3 vs LGD-4033
A side-by-side research comparison of IGF-1 LR3 and LGD-4033 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | IGF-1 LR3 | LGD-4033 |
|---|---|---|
| Full name | Insulin-like Growth Factor-1 Long R3 | Ligandrol (LGD-4033) |
| Category | Muscle Growth | Muscle Growth |
| Status | Research compound | Investigational |
| Mechanism | Activates IGF-1R while evading IGFBP sequestration. Triggers PI3K/Akt/mTOR for protein synthesis, satellite cell proliferation, and amino acid uptake into muscle. | Selectively binds androgen receptors in muscle and bone, activating anabolic gene transcription while avoiding prostate activity. |
| Molecular weight | 9,111 Da | 338.25 Da |
| Half-life | 20-30 hours (vs 15 min native) | ~24-36 hours |
| Bioavailability | High (SubQ/IM) | ~90% oral |
| Typical dose | 20-50 mcg | 5-10 mg |
| Frequency | Daily (post-workout) | Once daily |
| Route | Subcutaneous or intramuscular injection | Oral |
IGF-1 LR3 reported benefits
- Potent anabolic effects
- Hyperplasia (new muscle cells)
- Extended half-life
- Enhanced recovery
- Improved nutrient partitioning
- Satellite cell activation
LGD-4033 reported benefits
- Significant lean mass gains
- Bone density improvement
- Oral convenience
- Selective tissue activity
Related comparisons
Research and educational reference only. Not medical advice.